5.86  -0.49 (-7.72%)		01-14 12:58
Open: 6.34 High: 6.34 Volume: 45,203		Pre. Close: 6.35 Low: 5.71 Market Cap: 213(M)

Short term
Mid term
Targets	6-month :	7.95	1-year :	9.23
Resists	First :	6.8	Second :	7.9
Pivot price	6.49
Supports	First :	5.03	Second :	4.18
MAs	MA(5) :	6.75	MA(20) :	6.33
	MA(100) :	4.87	MA(250) :	3.1
MACD	MACD :	0.1	Signal :	0.1
%K %D	K(14,3) :	28.9	D(3) :	51.8
RSI	RSI(14): 45.1
52-week	High :	16.34	Low :	0.89

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ARMP ] has closed above bottom band by 14.3%. Bollinger Bands are 3.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	6.83 - 6.88	6.88 - 6.91
Low:	5.74 - 5.79	5.79 - 5.83
Close:	6.28 - 6.36	6.36 - 6.41

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.

Tue, 13 Jan 2026
Armata Pharmaceuticals Advances AP-SA02 to Phase 3 Study - TradingView — Track All Markets

Tue, 13 Jan 2026
Antibiotic-resistant Staphylococcus aureus study moves to Armata Phase 3 - Stock Titan

Mon, 05 Jan 2026
Jones Trading Initiates Coverage on Armata Pharmaceuticals (ARMP - GuruFocus

Tue, 18 Nov 2025
Armata Pharmaceuticals Announces Key Opinion Leader Webinar on S. aureus Bacteremia and AP-SA02 Hosted by Jones Research on November 25th at 10:00am EST - PR Newswire

Wed, 12 Nov 2025
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance

Wed, 12 Nov 2025
Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.